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Background: Controversy exists on whether urinary tract infection (UTI) is a risk factor for urinary bladder cancer (UBC). Here, the
association is investigated using data from one of the largest bladder cancer case–control studies worldwide.
Methods: Information on (i) history and age at onset of regular cystitis (‘regular low-UTI’) and (ii) number and age at onset of UTI
treated with antibiotics (‘UTI-ab’) from 1809 UBC patients and 4370 controls was analysed. Odds ratios (ORs) and 95% confidence
intervals (CI) adjusted for age, education, smoking, and use of aspirin/ibuprofen were generated, for men and women separately.
Results: Regular low-UTI was associated with an increased UBC risk (men: OR (95% CI) 6.6 (4.2–11); women: 2.7 (2.0–3.5)), with
stronger effects in muscle-invasive UBC. Statistically significant decreased risks (ORs B0.65) were observed for up to five UTI-ab,
specifically in those who (had) smoked and experienced UTI-ab at a younger age. In women, UTI experienced after menopause
was associated with a higher UBC risk, irrespective of the number of episodes.
Conclusions: Regular cystitis is positively associated with UBC risk. In contrast, a limited number of episodes of UTI treated with
antibiotics is associated with decreased UBC risk, but not in never-smokers and postmenopausal women.
Urinary tract infections (UTIs) refer to the presence of microbial
pathogens in the urethra or bladder (lower urinary tract), or ureter
and pelvis of the kidney (upper urinary tract). In men, the prostate
may be involved as well. UTIs are among the most prevalent
infectious diseases with varying frequencies among sexes and age
categories. About 80% of UTIs occur in women; it is estimated that
40– 50% of females experience at least one symptomatic UTI and
that half of them will experience a recurrence within 1 year
(Foxman, 2010; Salvatore et al, 2011). The majority of UTIs is
caused by E. coli and manifests as cystitis. Risk factors for
(recurrent) UTI include obstruction of the urinary tract, use of a
bladder catheter, a suppressed immune system, oestrogen defi-
ciency, a genetic predisposition, and sexual intercourse, and may
differ between men and pre- and postmenopausal women
(Foxman et al, 2000; Nicolle, 2002; Foxman, 2010; Salvatore
et al, 2011).
There is strong evidence linking infection of the bladder by
Schistosoma haematobium, endemic in certain low- and middle-
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income countries but rare in high-income countries, and by spinal
cord injury-related catheter use to squamous cell carcinoma of the
bladder (IARC Working Group on the Evaluation of Carcinogenic
Risks to Humans, 1994; Hess et al, 2003). However, whether
common, recurrent UTIs are involved in the aetiology of urothelial
carcinoma of the bladder remains unclear. Several epidemiological
studies, most from the second half of the twentieth century and
conducted in small populations, have investigated the association
between episodes of (lower) UTI and the risk of urinary bladder
cancer (UBC). The majority of these studies report increased UBC
risks for any vs no UTI, in both men and women (Wynder et al,
1963; Dunham et al, 1968; Howe et al, 1980; Kantor et al, 1984;
Claude et al, 1986; La Vecchia et al, 1991; Kunze et al, 1992;
Sturgeon et al, 1994; Jhamb et al 2007; Sun et al, 2013), whereas
some do not support a positive association (Piper et al, 1986; Kjaer
et al, 1989; Gonza´lez et al, 1991; Jiang et al, 2009). A few studies
specifically address the number of UTI episodes or the duration
between UTI and UBC diagnosis, the latter to prevent potential
misclassification. Overall, positive associations tend to weaken as
the time lag between UTI and UBC increases (Gonza´lez et al, 1991;
La Vecchia et al, 1991; Sun et al, 2013) and the number of UTIs
decreases (Kantor et al, 1984; La Vecchia et al, 1991). In contrast to
these findings, Jhamb et al (2007) and Jiang et al (2009) report a
decreased risk of UBC with an increasing number of kidney and
bladder infections with the lowest risk for more than three episodes
of infection.
In this study, we analysed data of the Nijmegen Bladder
Cancer Study (NBCS), one of the largest case–control studies for
UBC worldwide, as to gain better insights into the role of
recurrent infections of the (lower) urinary tract as a risk factor
for UBC.
MATERIALS AND METHODS
Subjects and data extraction. Within the framework of the
NBCS, UBC patients living in the catchment area of seven hospitals
in the eastern part of the country were identified through the
Netherlands Cancer Registry (NCR) held by the Comprehensive
Cancer Centre the Netherlands (IKNL) (Kiemeney et al, 2008).
Patients diagnosed in the periods 1995–2006, 2006–2007, 2007–2009,
and 2009–2010 under the age of 76 years were batch-wise invited
for participation. Participants were asked to fill out a questionnaire
and donate a blood sample for DNA extraction. All patients had
histologically confirmed carcinoma of the urinary bladder. Data on
tumour characteristics were obtained via the NCR. The response
rate to the questionnaire was 65%.
Controls in the NBCS were individuals recruited for the
Nijmegen Biomedical Study (NBS), a population-based survey
that aimed to provide a generic reference group for case–control
studies. The NBS was conducted by the Departments for Health
Evidence and Clinical Chemistry of the Radboud University
Medical Center, Nijmegen, The Netherlands. In 2002, 22 451 age-
and sex-stratified inhabitants were randomly selected from the
demography registration of the municipality of Nijmegen and
invited to fill out a questionnaire and donate a blood sample. The
response rate to this first questionnaire was 43%, with a total of
9350 participants (54% female). A second, third, and fourth
questionnaire were sent out in 2005 (response rate 70%; n¼ 5594),
2008 (response rate 69%; n¼ 5613), and 2012 (response rate 51%;
n¼ 3831), respectively.
The study protocols of the NBCS and the NBS were approved by
the Institutional Review Board of the Radboud University Medical
Center, and all study subjects gave written informed consent
(Kiemeney et al, 2008) (NBCS: http://icbc.cancer.gov/member-
ship.html; NBS: http://www.nijmegenbiomedischestudie.nl).
By means of the NBCS and NBS questionnaire(s), information
on, among others, lifestyle, ethnicity, medical history, and family
history, was collected from the patients and controls. Data on UTIs
were retrieved via two questions: (i) Have you ever been diagnosed
by a physician with regular bladder infections (for the remainder of
this article abbreviated with regular low-UTI), and, if so, at what
age? (ii) Have you ever had a urinary tract infection for which you
were treated with antibiotics (abbreviated with UTI-ab) and, if so,
how often (1–2, 3–5, 6–10, or 11 times or more) and at what age
did you first have a UTI-ab? For patients, the latter question was
specifically posed for the period up to 2 years prior to UBC
diagnosis. For the NBS controls, data on regular low-UTI were
obtained in 2005 and data on UTI-ab were obtained in 2008. We
excluded those UTI-ab in controls that were reported to have
occurred within 2 years prior to filling out the questionnaire. For
regular low-UTI, those that occurred at or after age at UBC
diagnosis for patients (and filling out the questionnaire for
controls) were excluded.
In addition, questionnaire data on highest education, ethnicity,
smoking, and regular use during a minimum of 6 months of the
non-steroidal anti-inflammatory drugs aspirin and ibuprofen/
brufen (prior to UBC diagnosis) were extracted.
For this study, we selected UBC patients of self-reported
Caucasian ethnicity and controls that filled out questionnaires 1–3
(that contained information relevant for this study), had no prior
history of bladder cancer at time of recruitment, and were of self-
reported Caucasian ethnicity.
Statistical analysis. Univariable and multivariable logistic regres-
sion analyses were used to evaluate the association between regular
low-UTI and frequency of UTI-ab and bladder cancer risk. Odds
ratios (ORs) and corresponding 95% confidence intervals (CIs)
were adjusted for the following, potentially confounding, factors:
age at UBC diagnosis/at time of completing questionnaire (in
years), smoking status (categorical variable: never smokers, former
smokers, current smokers (i.e., those who had not stopped in the
year prior to the year of UBC diagnosis (for patients) or filling out
the questionnaire (for controls)), cumulative smoking exposure in
terms of pack-years of cigarettes, use of aspirin and ibuprofen/
brufen (yes/no), and education (categorical variable). Additional
analyses were conducted to determine whether the associations
differed for non-muscle invasive and muscle-invasive bladder
cancer, age at onset of UTI (below or above sex-specific median
age), menopausal state at onset UTI (using a threshold of 51 years
as proxy), and smoking status (never vs ever). All analyses were
stratified for gender. A (two-sided) P-value of less than 0.05 was
considered statistically significant. Statistical analyses were per-
formed using IBM SPSS Statistics for Windows, release 20.0.0.1
(IBM Corp., Armonk, NY, USA).
RESULTS
Characteristics of UBC patients and controls. This study
included 1809 UBC patients (81% male) and 4370 controls (45%
male). Average age of male patients and controls was 63 and 62
years, respectively. Average age for female patients and controls
was 61 and 57 years. Patients were less educated, were more likely
to smoke, and more likely to have regularly used non-steroidal
anti-inflammatory drugs, as compared with controls. Among the
patients, 83% of male and 75% of female cases were categorised as
non-muscle invasive bladder cancer patients (stages Ta, T1, and
CIS). Almost all patients were diagnosed with urothelial carcinoma
(Table 1).
The frequencies of regular low-UTI and UTI-ab in patients and
controls are given in Table 2. As expected, these were higher in
women compared with men. The overlap in reported regular low-
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UTI and frequent UTI-ab by the study participants was
considerable (Table 3).
Association between UTI and UBC. A positive history of regular
low-UTI was associated with an increased risk of UBC in both
men (ORadjusted (95% CI) 6.6 (4.2–11)) and women (ORadj 2.7
(2.0–3.5)). In contrast, a positive history of UTI-ab was associated
with a decreased UBC risk, again in both men (ORadj 0.76
(0.61–0.94)) and women (ORadj 0.82 (0.64–1.1)). Stratification on
frequency of UTI-ab revealed that the protective effect was only
seen for up to five episodes of infection. An increased UBC risk was
observed for men with more than 10 UTI-ab episodes (ORadj 6.0
(1.2–30)) but numbers of male patients and controls in this
stratum were low (Table 2).
As the symptoms of bladder cancer may be confused with those
of a UTI, we repeated the analyses while omitting those regular
low-UTI or UTI-ab that took place within 5 years prior to the date
of diagnosis of bladder cancer (for patients) or the questionnaire
(for controls). Resulting risks were only slightly changed (Table 2)
and for subsequent analyses, we did not take the time lag between
UTI and UBC into account.
The stratified analyses (Table 4) indicated that the UBC risk
increase for regular low-UTI and multiple episodes of UTI-ab was
more pronounced in muscle-invasive bladder cancer compared
with non-muscle invasive bladder cancer. The UBC risk decrease
for a low number of UTI-ab is specifically observed in those who
(had) smoked and the group of subjects that experienced UTI at a
younger age (i.e., below the sex-specific median age at onset UTI).
For women, large differences in UTI-ab-associated risks for
premenopausal (p51 years) vs postmenopausal (451 years) state
were seen. The decrease of UBC risk for a limited number of UTI-
ab was only observed for premenopausal state UTI; a strong
increase in risk for UBC was observed for postmenopausal state
UTI-ab, irrespective of the number of episodes. Omission of UTI-
ab that occurred within 5 years prior to UBC diagnosis/
questionnaire led to even higher risks (data not shown).
DISCUSSION
Infection of the urinary tract has been thought to play a role in
urinary bladder carcinogenesis, but has only been particularly
evidenced and widely accepted for the association between
schistosomiasis and catheter use in spinal cord injury with
squamous cell carcinoma (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans, 1994; Hess et al,
2003). We show in this case–control study that UTI in the form
of regular cystitis is associated with an increased risk of
carcinoma of the bladder and that a limited number of UTI
treated with antibiotics (i.e., p5) is associated with decreased
UBC risk.
We analysed data on regular cystitis and the number of UTI
treated with antibiotics. These two variables are both measures of
recurrent UTI but do not reflect the exact same information. In
addition to differential recall bias or misclassification, disparity
between results for regular low-UTI and a high number of UTI-ab
as observed in our study can be contributed to the distinctions
between (i) regular and a high number of episodes, (ii) cystitis and
UTIs, and (iii) use and no use of antibiotics. Indeed, disparate risks
for bladder and kidney infections have been reported by Jiang et al
(2009) and Jhamb et al (2007). Also, inhibition of cell proliferation
and anti-cancer effects in transitional cell carcinoma cell lines for
two of the most commonly used antibiotics in UTI in Dutch
Table 1. Baseline characteristics of the study population









Mean age in years (sd) 61.8 (15.9) 62.9 (9.3) 56.5 (16.5) 61.3 (10.6)
Highest education
Primary 122 (6.2) 213 (14.6) 184 (7.7) 70 (20.2)
Lower vocational secondary 305 (15.5) 363 (24.8) 307 (12.9) 82 (23.7)
Intermediate general secondary 246 (12.5) 202 (13.8) 432 (18.1) 87 (25.1)
Intermediate vocational secondary 296 (15.1) 219 (15.0) 277 (11.6) 36 (10.4)
Higher general secondary 186 (9.5) 84 (5.7) 276 (11.6) 13 (3.8)
Higher vocational secondary 379 (19.3) 219 (15.0) 580 (24.3) 39 (11.3)
University 428 (21.8) 113 (7.7) 331 (13.9) 5 (1.4)
Other 3 (0.2) 49 (3.4) 1 (0.0) 14 (4.0)
Smoking status
Never 483 (24.5) 120 (8.2) 1034 (43.3) 88 (25.4)
Former 1170 (59.3) 860 (58.8) 996 (41.7) 131 (37.9)
Current 319 (16.2) 482 (33.0) 358 (15.0) 127 (36.7)
Mean pack-years cigarettes (sd) 19.1 (17.1) 27.0 (19.2) 14.1 (15.2) 22.5 (16.0)
NSAIDS
Aspirin 474 (24.0) 524 (35.8) 462 (19.3) 126 (36.4)
Ibuprofen/brufen 232 (11.8) 239 (16.3) 503 (21.0) 73 (21.1)
Tumour stage
NMIBC (Ta, T1, CIS) — 1220 (83.4) — 260 (75.1)
MIBC (XT2) — 183 (12.5) — 70 (20.2)
Missing — 60 (4.1) — 16 (4.6)
Tumour histologya
Urothelial carcinoma — 1440 (98.4) — 327 (94.5)
Squamous cell carcinoma — 4 (0.3) — 11 (3.2)
Adenocarcinoma — 5 (0.3) — 6 (1.7)
Other — 14 (1.0) — 2 (0.6)
Abbreviations: NSAIDS¼ non-steroidal anti-inflammatory drugs; NMIBC¼ non-muscle invasive bladder cancer; MIBC¼muscle invasive bladder cancer; sd¼ standard deviation.
apredominant histology according to the 1995 to 2000 ICD-O-2 and the 2000 to 2006 ICD-O-3.
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practice (i.e., nitrofurantoin and trimethoprim) have been
described (Seay et al, 1996; Kamat and Lamm, 2004). However,
as most UTIs manifest as cystitis and are treated with antibiotics,
these latter two distinctions may not fully account for the observed
disparity in effects.
One possible explanation for the fact that regular cystitis
associates positively with UBC is the mediating role of nitric oxide
(NO). NO is produced during inflammation by the activation of
inducible nitric oxide synthase (iNOS) and may promote tumour
growth and proliferation (Xu et al, 2002; Lin et al, 2003). Indeed,
studies have shown that iNOS-specific proteins and ribonucleic
acid products are present in urothelial tumours of the bladder but
not in control bladder tissue (Swana et al, 1999; Lin et al, 2003). In
addition, UTIs are also associated with increased iNOS expression
in animal models (Mysorekar et al, 2002; Poljakovic and Persson,
2003) and nitrative DNA damage has been associated with bladder
cancer induced by Schistosoma haematobium infection (Ma et al,
2011), suggesting that repeated activation of iNOS and thus NO
production in both recurrent UTI episodes and in UBC may be a
common pathway involved in urothelial response. One may
Table 2. Associations between regular bladder infection (regular low-UTI) and UTI treated with antibiotics (UTI-ab) and urinary















No 1950 (98.8) 1327 (90.7) Ref Ref 2039 (85.1) 232 (67.1) Ref Ref
Yes 24 (1.2) 136 (9.3) 8.3 (5.4–13) 6.6 (4.2–11) 357 (14.9) 114 (32.9) 2.8 (2.2–3.6) 2.7 (2.0–3.5)
Omission p5 yearsb
No 1959 (99.2) 1387 (94.8) Ref Ref 2110 (88.1) 263 (76.0) Ref Ref
Yes 15 (0.8) 76 (5.2) 7.2 (4.1–13) 5.5 (3.1–9.9) 286 (11.9) 83 (24.0) 2.3 (1.8–3.1) 2.2 (1.6–3.0)
UTI-ab
No 1569 (82.9) 1174 (85.9) Ref Ref 1110 (48.4) 169 (54.0) Ref Ref
Yes 324 (17.1) 192 (14.1) 0.79 (0.65–0.96) 0.76 (0.61–0.94) 1182 (51.6) 144 (46.0) 0.80 (0.63–1.0) 0.82 (0.64–1.1)
Omission p5 yearsc
No 1623 (85.7) 1231 (90.1) Ref Ref 1224 (53.4) 187 (59.7) Ref Ref
Yes 270 (14.3) 135 (9.9) 0.66 (0.53–0.82) 0.63 (0.49–0.80) 1068 (46.6) 126 (40.3) 0.77 (0.61–0.98) 0.72 (0.56–0.94)
Number of UTI-ab
0 1569 (83.7) 1174 (87.4) Ref Ref 1110 (49.6) 169 (58.5) Ref Ref
1–2 217 (11.6) 103 (7.7) 0.63 (0.50–0.81) 0.63 (0.48–0.82) 530 (23.7) 43 (14.9) 0.53 (0.38–0.76) 0.63 (0.43–0.91)
3–5 75 (4.0) 42 (3.1) 0.75 (0.51–1.1) 0.82 (0.54–1.2) 333 (14.9) 32 (11.1) 0.63 (0.42–0.94) 0.65 (0.43–1.0)
6–10 11 (0.6) 14 (1.0) 1.7 (0.77–3.8) 1.2 (0.52–2.9) 159 (7.1) 22 (7.6) 0.91 (0.57–1.5) 1.1 (0.64–1.8)
X11 2 (0.1) 11 (0.8) 7.4 (1.6–33) 6.0 (1.2–30) 107 (4.8) 23 (8.0) 1.4 (0.88–2.3) 1.1 (0.64–1.8)
Omission p5 yearsc
0 1623 (86.6) 1227 (91.3) Ref Ref 1224 (54.6) 186 (64.4) Ref Ref
1–2 173 (9.2) 73 (5.4) 0.56 (0.42–0.74) 0.55 (0.41–0.75) 450 (20.1) 34 (11.8) 0.50 (0.34–0.72) 0.56 (0.37–0.83)
3–5 66 (3.5) 27 (2.0) 0.54 (0.34–0.85) 0.59 (0.36–0.97) 311 (13.9) 29 (10.0) 0.61 (0.41–0.92) 0.60 (0.39–0.94)
6–10 11 (0.6) 8 (0.6) 0.96 (0.39–2.4) 0.70 (0.26–1.9) 149 (6.7) 18 (6.2) 0.80 (0.48–1.3) 0.91 (0.53–1.6)
X11 1 (0.1) 9 (0.7) 11.9 (1.5–94) 8.2 (0.9–73) 107 (4.8) 22 (7.6) 1.4 (0.83–2.2) 1.0 (0.59–1.7)
Abbreviations: CI¼ confidence interval; OR¼odds ratio; UTI¼urinary tract infection; UTI-ab¼urinary tract infection treated with antibiotics.
aOR adjusted for age (at diagnosis for patients and at filling out questionnaire for controls), highest education, smoking status (current, never, former), pack-years cigarettes, use of aspirin, use
of ibuprofen/brufen.
bRegular low-UTI for which the number of years between age of UTI and filling out questionnaire (controls)/age of UBC diagnosis (patients) was equal to or less than 5 years were set to zero.
Among those who reported regular low-UTI, age at regular low-UTI was available in 15 (63%) male controls and 96 (71%) male patients and in 266 (75%) female controls and 89 (78%) female
patients.
cUTI-ab for which the number of years between age of first UTI and filling out questionnaire (controls)/age of UBC diagnosis (patients) was 2–5 years were set to zero. Among those who
reported UTI-ab, age at first UTI-ab was available in 243 (75%) male controls and 118 (62%) male patients and in 738 (62%) female controls and 90 (63%) female patients.
Table 3. Overlap in reported regular bladder infections (regular low-UTI) and episodes of UTI-ab for patients and controls and
men and women separately
Men Women
Controls N (%) Patients N (%) Controls N (%) Patients N (%)
Regular low-UTI No Yes No Yes No Yes No Yes
Number of UTI-ab
0 1585 (99.8) 3 (0.2) 1112 (94.7) 62 (5.3) 1114 (97.5) 29 (2.5) 146 (86.4) 23 (13.6)
1–2 199 (98.5) 3 (1.5) 86 (83.5) 17 (16.5) 474 (93.9) 31 (6.1) 34 (79.1) 9 (20.9)
3–5 63 (88.7) 8 (11.3) 20 (47.6) 22 (52.4) 226 (69.1) 101 (30.9) 20 (62.5) 12 (37.5)
6–10 5 (45.5) 6 (54.5) 3 (21.4) 11 (78.6) 67 (42.7) 90 (57.3) 4 (18.2) 18 (81.8)
X11 1 (50.0) 1 (50.0) 5 (45.5) 6 (54.5) 27 (25.2) 80 (74.8) 0 (0.0) 23 (100.0)
Abbreviations: UTI¼urinary tract infection; UTI-ab¼ urinary tract infection treated with antibiotics. For controls, those UTI-ab episodes that were experienced after the questionnaire on regular
low-UTI were omitted as to account for the time lag between the questionnaires on regular low-UTI and UTI-ab.
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Table 4. Associations between regular bladder infection (regular low-UTI) and UTI-ab and urinary bladder cancer, stratified by
stage of bladder cancer, median age at onset of infection, menopausal state at onset infection (i.e., older than 51 years of age or


















Tumour stage NMIBC MIBC NMIBC MIBC
Regular low-UTI
No 1950/1119 Ref 1950/153 Ref 2039/180 Ref 2039/40 Ref
Yes 24/101 5.7 (3.5–9.2) 24/30 14 (7.4–27) 357/80 2.4 (1.8–3.3) 357/30 4.4 (2.6–7.4)
UTI-ab
No 1569/978 Ref 1569/148 Ref 1110/127 Ref 1110/32 Ref
Yes 324/160 0.74 (0.59–0.93) 324/24 0.80 (0.49–1.3) 1182/108 0.83 (0.62–1.1) 1182/30 0.86 (0.50–1.5)
Number of UTI-ab
0 1569/978 Ref 1569/148 Ref 1110/127 Ref 1110/32 Ref
1–2 217/86 0.62 (0.47–0.82) 217/12 0.57 (0.30–1.1) 530/36 0.69 (0.46–1.0) 530/6 0.48 (0.19–1.2)
3–5 75/33 0.75 (0.48–1.2) 75/7 1.2 (0.52–2.8) 333/22 0.61 (0.38–1.0) 333/7 0.65 (0.26–1.6)
6–10 11/12 1.1 (0.47–2.7) 11/1 1.3 (0.16–11) 159/18 1.1 (0.66–2.0) 159/4 1.2 (0.39–3.4)
X11 2/10 6.5 (1.3–32) 2/1 6.8 (0.50–92) 107/15 0.94 (0.51–1.7) 107/7 1.5 (0.59–3.8)
Age regular low-
UTI/UTI-abb
pmedian age 4median age pmedian age 4median age
Regular low-UTI
No 1950/1327 Ref 1950/1327 Ref 2039/232 Ref 2039/232 Ref
Yes 5/24 8.0 (2.9–22) 10/72 7.8 (3.9–16) 122/24 2.2 (1.3–3.8) 144/65 3.6 (2.5–5.2)
UTI-ab
No 1569/1174 Ref 1569/1174 Ref 1110/169 Ref 1110/169 Ref
Yes 108/31 0.38 (0.24–0.59) 135/87 0.84 (0.62–1.1) 330/28 0.69 (0.43–1.1) 408/62 1.0 (0.75–1.5)
Number of UTI-ab
0 1569/1174 Ref 1569/1174 Ref 1110/169 Ref 1110/169 Ref
1–2 78/18 0.33 (0.19–0.58) 93/47 0.64 (0.43–0.94) 123/8 0.64 (0.28–1.4) 236/24 0.79 (0.49–1.3)
3–5 25/7 0.35 (0.14–0.88) 32/23 1.1 (0.61–2.0) 101/5 0.43 (0.17–1.1) 98/13 0.86 (0.46–1.6)
6–10 3/3 0.89 (0.14–5.6) 4/6 1.4 (0.37–5.3) 53/4 0.67 (0.23–2.0) 43/12 2.0 (0.99–4.2)
X11 0/3 — 2/6 4.8 (0.90–25) 47/8 0.89 (0.36–2.2) 22/11 2.1 (0.95–4.9)
Menopausal state Pre (p51 years) Post (451 years)
Regular low-UTI
No 2039/232 Ref 2039/232 Ref
Yes 211/57 3.1 (2.1–4.5) 55/32 3.4 (2.1–5.7)
UTI-ab
No 1110/169 Ref 1110/169 Ref
Yes 632/68 0.79 (0.57–1.1) 106/74 5.0 (3.4–7.4)
Number of UTI-ab
0 1110/169 Ref 1110/169 Ref
1–2 302/21 0.59 (0.36–0.98) 57/21 2.6 (1.4–4.5)
3–5 173/13 0.55 (0.30–1.0) 26/19 6.3 (3.2–12)
6–10 81/13 1.3 (0.68–2.6) 15/8 4.0 (1.5–11)
X11 64/16 1.2 (0.62–2.3) 5/7 10 (3.0–35)
Smoking statusc Never Ever Never Ever
Regular low-UTI
No 478/110 Ref 1470/1216 Ref 867/56 Ref 1165/176 Ref
Yes 5/10 7.4 (3.0–24) 19/126 6.4 (3.9–11) 167/32 2.8 (1.7–4.6) 189/82 2.6 (1.9–3.7)
UTI-ab
No 406/90 Ref 1161/1083 Ref 481/38 Ref 625/131 Ref
Yes 59/18 1.1 (0.61–2.1) 265/174 0.71 (0.57–0.88) 498/43 1.1 (0.67–1.7) 680/101 0.71 (0.52–0.96)
Number of UTI-ab
0 406/90 Ref 1161/1083 Ref 481/38 Ref 625/131 Ref
1–2 40/98 0.87 (0.39–1.9) 177/94 0.58 (0.44–0.77) 211/14 0.98 (0.51–1.9) 318/29 0.51 (0.33–0.80)
3–5 16/5 1.2 (0.39–3.5) 59/37 0.76 (0.48–1.2) 144/14 1.2 (0.60–2.3) 188/18 0.43 (0.25–0.76)
6–10 1/1 3.3 (0.20–54) 10/13 1.1 (0.46–2.6) 76/4 0.67 (0.23–2.0) 81/18 1.2 (0.68–2.2)
X11 0/1 — 2/10 4.6 (0.93–22) 45/7 1.4 (0.56–3.5) 62/16 0.92 (0.49–1.7)
Abbreviations: CI¼ confidence interval; MIBC¼muscle invasive bladder cancer; NMIBC¼non-muscle invasive bladder cancer; OR¼odds ratio; UTI¼ urinary tract infection; UTI-ab¼urinary
tract infection treated with antibiotics.
aOR adjusted for age (at diagnosis for patients and at filling out questionnaire for controls), highest education, smoking status (current, never, former), pack-years cigarettes, use of aspirin, use
of ibuprofen/brufen.
bMedian ages (in years) at onset UTI (with omission UTIo¼ 5 years prior to age at UBC diagnosis/questionnaire): regular low-UTI males: 50.0; regular low-UTI females: 25; UTI-ab males: 42.0;
UTI-ab females: 24.5
cOR adjusted for age (at diagnosis for patients and at filling out questionnaire for controls), highest education, use of aspirin, pack-years cigarettes, use of ibuprofen/brufen.
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speculate that the protective effect of a limited number of UTI
treated with antibiotics suggests that the beneficial anti-cancer
effect of antibiotics as described by Seay et al (1996) and Kamat
and Lamm (2004) outweighs the detrimental effects of (sporadic)
infection and subsequent NO production. It is, however, unclear
whether only a few short courses of antibiotics can decrease
bladder cancer risk. Note that the decreased rate of UTI-ab in
bladder cancer patients compared with controls was not seen for
the few UBC patients in our population with squamous cell and
adenocarcinoma but only for urothelial carcinoma (as predomi-
nant histology) (data not shown).
Exact comparison between our findings and those from
previous studies is hampered by the fact that only few studies
have addressed the number, location, and treatment of the UTIs in
detail. The observed increased UBC risk for regular cystitis
confirms findings from Kantor et al (1984) and La Vecchia et al
(1991) whose studies show that more than three episodes of cystitis
increases UBC risk. The observed decreased risk of UBC for a
limited number of UTI is in line with a recent study from Jiang
et al (2009) in which one, two to three, and more than three
episodes of cystitis were associated with reduced risk of UBC in
women. Unfortunately, those women who experienced more than
three episodes were combined in one category, thereby preventing
us to evaluate the association for those with a higher number of
episodes in more detail. Most studies, however, report a higher
UBC risk for a patient-reported positive history of UTI (Wynder
et al, 1963; Jhamb et al, 2007).
A number of the previous studies into the association between
UTI and UBC have described a decrease in the OR for UTI and
bladder cancer risk after excluding those UTI that occurred within
the years prior to UBC diagnosis (Gonza´lez et al, 1991; La Vecchia
et al, 1991; Jhamb et al, 2007; Jiang et al, 2009; Sun et al, 2013).
These findings support the existence of a diagnostic bias. This is
underlined by studies that have described UTI diagnosis as a cause
for delay in bladder cancer diagnosis (Henning et al, 2013; Cohn
et al, 2014). The results of our study were, however, only
marginally affected by omission of infections occurring within 5
years prior to UBC diagnosis.
We showed that our results for UTI-ab were similar for men
and women; the increased UBC risk for regular cystitis was
higher in men though. However, note that, in contrast to women,
regular cystitis is rare among the male population. Further
stratified analyses, more or less hampered by limited numbers in
specific subcategories, did identify deviating findings in some
subgroups. Timing of the onset of UTI was found to be of
importance; the protective effect of a small number of UTI-ab
was only found for those UTI that were experienced at a
relatively young age (i.e., below the sex-specific median age) and
the increase in UBC risk for recurrent cystitis was more
pronounced for an older age of UTI-onset. Especially the
increased risk of bladder cancer for history of UTI-ab,
irrespective of frequency, in postmenopausal women was striking
and warrants further research. It is notable that these subgroups
that showed stronger increased UBC risk for recurrent cystitis,
that is, men, those with UTI onset at an older age, and
postmenopausal women, are also more likely to experience a
complicated and recurrent (course of) UTI because of the
presence of anatomical, functional, or metabolic conditions (e.g.,
prostatitis, diabetes, vaginal atrophy). Furthermore, the higher
UBC risk for regular cystitis was much stronger in muscle-
invasive bladder cancer compared with non-muscle invasive
bladder cancer, in line with Kantor et al (1984) and Sturgeon
et al (1994). The protective effect of a small number of UTI-ab
was only seen in (former) smokers; we could not confirm the
positive interaction between smoking and history of cystitis on
UBC risk as reported in earlier studies (Kantor et al, 1984; La
Vecchia et al, 1991).
In conclusion, our study showed a protective effect on UBC risk
for a small number (p5) of UTI episodes treated with antibiotics,
specifically at a younger age of onset and in (former) smokers, and
increased UBC risk for regular cystitis. We underline the
importance of considering the total number of UTI, age at onset,
location in the urinary tract, and use of antibiotics when
considering the association of UTI with bladder cancer in future
research as to allow for further unravelling of their separate effects.
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